busulfan has been researched along with Heart Diseases in 8 studies
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support." | 9.08 | A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995) |
| "A case is reported of pericardial fibrosis after busulfan treatment in a man with chronic myeloid leukaemia." | 7.67 | Pericardial fibrosis following busulfan treatment. ( de Maat, CE; Terpstra, W, 1989) |
| "Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years." | 5.09 | The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support." | 5.08 | A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995) |
| "A case is reported of pericardial fibrosis after busulfan treatment in a man with chronic myeloid leukaemia." | 3.67 | Pericardial fibrosis following busulfan treatment. ( de Maat, CE; Terpstra, W, 1989) |
| "Twenty-five patients developed arrhythmias at a median of 3 days post transplant, in 19 patients hemodynamic compromise occurred and mechanical ventilation was required in 15 patients." | 1.36 | Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. ( Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peres, E | 1 |
| Levine, JE | 1 |
| Khaled, YA | 1 |
| Ibrahim, RB | 1 |
| Braun, TM | 1 |
| Krijanovski, OI | 1 |
| Mineishi, S | 1 |
| Abidi, MH | 1 |
| MARTINEZ MALDONADO, M | 1 |
| MENENDEZ CORRADA, R | 1 |
| RIVERADESALA, A | 1 |
| Przepiorka, D | 1 |
| Nath, R | 1 |
| Ippoliti, C | 1 |
| Mehra, R | 1 |
| Hagemeister, F | 1 |
| Diener, K | 1 |
| Dimopoulos, M | 1 |
| Giralt, S | 1 |
| Khouri, I | 1 |
| Samuels, B | 1 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Treleaven, J | 1 |
| Mainwaring, P | 1 |
| Kulkarni, S | 1 |
| Pandha, H | 1 |
| Bhagwati, N | 1 |
| Horton, C | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Jaffe, N | 1 |
| Weinberger, A | 1 |
| Pinkhas, J | 1 |
| Sandbank, U | 1 |
| Shaklai, M | 1 |
| de Vries, A | 1 |
| Kobayashi, I | 1 |
| Didisheim, P | 1 |
| Terpstra, W | 1 |
| de Maat, CE | 1 |
1 review available for busulfan and Heart Diseases
| Article | Year |
|---|---|
Late side effects of treatment: skeletal, genetic, central nervous system, and oncogenic.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antineoplastic Agents; Busulfan; Carcinogens; Centra | 1976 |
2 trials available for busulfan and Heart Diseases
| Article | Year |
|---|---|
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemic | 1995 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chem | 2000 |
5 other studies available for busulfan and Heart Diseases
| Article | Year |
|---|---|
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.
Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; | 2010 |
DIAGNOSTIC VALUE OF ALKALINE PHOSPHATASE IN LEUKOCYTES.
Topics: Alkaline Phosphatase; Busulfan; Celiac Disease; Diagnosis, Differential; Drug Therapy; Gout; Heart D | 1964 |
Endocardial fibrosis following busulfan treatment.
Topics: Aged; Autopsy; Busulfan; Endocardium; Female; Heart Diseases; Heart Ventricles; Humans; Leukemia, My | 1975 |
Cardiopulmonary dysfunctions caused by intravenous collagen-induced release of ADP and ATP from platelets.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Blood Platelets; Busulfan; Central Venous Pr | 1975 |
Pericardial fibrosis following busulfan treatment.
Topics: Busulfan; Fibrosis; Heart Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; | 1989 |